DexCom, Inc. (LON:0A4M)
London flag London · Delayed Price · Currency is GBP · Price in USD
69.29
-13.90 (-16.71%)
At close: Mar 14, 2025

DexCom Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians.

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes.

The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.
Country United States
Founded 1999
Industry Electromedical and Electrotherapeutic Apparatus
Employees 10,300
CEO Kevin Sayer

Contact Details

Address:
6340 Sequence Drive
San Diego, Delaware 92121
United States
Phone 858 200 0200
Website dexcom.com

Stock Details

Ticker Symbol 0A4M
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 3845

Key Executives

Name Position
Kevin Sayer Chief Executive Officer
Jereme Sylvain Chief Financial Officer
Jacob Leach Chief Operating Officer
Sean Christensen Head of Investor Relations